FORMULATION DEVELOPMENT OF MICROSPONGE BASED DELAYED RELEASE DOSAGE FORM OF LANSOPRAZOLE

The aim of study is to develop microsponge based delayed release dosage form, technique used to manufacture microsponge was quasi emulsion diffusion technique. Eudragit L 100 and Eudragit S 100 polymer is used to incorporate lansoprazole in microsponge. Lansoprazole is acid labile drug hence release of lansoprazole was delayed from acid environment. Microsponge contains porous polymeric microspheres, typically 100 – 250 μm in diameter. Compatibility of the drug with adjuncts was studied by DSC. Production yield, loading efficiency, particle size analysis, surface morphology and in-vitro release studies were carried out. Optimized microsponge blended with other diluents and filled in capsules. Blend containing lansoprazole Microsponge were evaluated for SeDeM parameters to check its flow. The microsponge formulation F2 showed delayed release of lansoprazole in buffer stage pH 6.8 bypassing the acidic stage. The result reveals that developed microsponge are cost effective and can be used as a delivery system for acid labile drug lansoprazole to avoid its degradation in acidic media of the stomach. SeDeM technique can be employed for successive prediction powder blend performance.